目的探讨血府逐瘀胶囊联合顺铂对小鼠Lewis肺癌移植瘤血管新生及血管内皮生长因子A(VEGFA)、血管内皮细胞生长因子受体2(VEGFR2)表达的影响。方法从75只C57BL/6小鼠中随机取15只作为正常组,其余小鼠均进行Lewis肺癌荷瘤造模。将造模成功...目的探讨血府逐瘀胶囊联合顺铂对小鼠Lewis肺癌移植瘤血管新生及血管内皮生长因子A(VEGFA)、血管内皮细胞生长因子受体2(VEGFR2)表达的影响。方法从75只C57BL/6小鼠中随机取15只作为正常组,其余小鼠均进行Lewis肺癌荷瘤造模。将造模成功的60只小鼠随机分为模型组、顺铂组、血府逐瘀胶囊组、血府逐瘀胶囊联合顺铂组,每组15只。血府逐瘀胶囊组给予血府逐瘀胶囊0.36 g/kg灌胃,模型组给予生理盐水灌胃,均2次/d;顺铂组给予2 mg/kg的顺铂腹腔注射,2 d 1次;血府逐瘀胶囊联合顺铂组给予0.36 g/kg血府逐瘀胶囊灌胃(2次/d)和2 mg/kg的顺铂腹腔注射(2 d 1次);正常组不给予任何干预。各组连续干预15 d后,统计存活率,摘取瘤组织并称量瘤重,计算抑瘤率,免疫组化法检测肿瘤组织中微血管数量,ELISA法测定血浆VEGFA、碱性成纤维细胞生长因子(bFGF)水平,免疫印迹法检测肿瘤组织中VEGFA、VEGFR2蛋白表达情况。结果顺铂组和血府逐瘀胶囊联合顺铂组小鼠存活率明显高于模型组和血府逐瘀胶囊组(P均<0.05);血府逐瘀胶囊联合顺铂组瘤重明显低于其他组(P均<0.05),抑瘤率明显高于顺铂组和血府逐瘀胶囊组(P均<0.05),肿瘤组织中微血管数明显少于模型组和血府逐瘀胶囊组(P均<0.05);顺铂组瘤重明显低于模型组和血府逐瘀胶囊组(P均<0.05),抑瘤率明显高于血府逐瘀胶囊组(P<0.05),肿瘤组织中微血管数明显少于其他组(P均<0.05)。顺铂组血浆VEGFA、bFGF水平和肿瘤组织中VEGFA、VEGFR2蛋白相对表达量均明显低于模型组(P均<0.05);血府逐瘀胶囊联合顺铂组血浆bFGF水平和肿瘤组织中VEGFR2蛋白相对表达量均明显低于模型组(P均<0.05)。结论血府逐瘀胶囊联合顺铂对Lewis肺癌荷瘤小鼠具有显著的抑瘤及抑制肿瘤血管新生的作用,其机制可能与VEGFA/VEGFR2信号通路相关。展开更多
Angiogenesis in atherosclerosis(AS)promotes plaque destabilization.miR-126 has a significant role in angiogenesis.Tetramethylpyrazine(TMP)and paeoniflorin(PF)have anti-atherosclerotic effects.However,the miR-126-relat...Angiogenesis in atherosclerosis(AS)promotes plaque destabilization.miR-126 has a significant role in angiogenesis.Tetramethylpyrazine(TMP)and paeoniflorin(PF)have anti-atherosclerotic effects.However,the miR-126-related mechanisms of TMP and PF combination(TMP-PF)on angiogenesis in AS have not been understood.To explore the mechanism of TMP-PF on angiogenesis in AS targeting miR-126.Human umbilical vein endothelial cells(HUVECs)were assigned into the control,model,TMP-PF,TMP-PF+miR-126 inhibitor,and simvastatin groups.HUVECs were transfected with miR-126 inhibitor or negative control,incubated with oxidized low-density lipoprotein(ox-LDL)to establish AS model,and then treated with TMP-PF or simvastatin.Cell proliferation,migration,and tube formation assays are conducted,and the expression of angiogenesis-related factors were detected by enzyme-linked immunosorbent assay(ELISA)and Western blotting.The expression level of miR-126 was confirmed by polymerase chain reaction(PCR).0x-LDL promoted HUVECs proliferation,migration,and tube formation,downregulated miR-126 expression,and increased the expression of VEGF,VEGFR2,bFGF,and FGFR1.TMP-PF inhibited proliferation,migration,and tube formation,upregulated miR-126 expression and decreased the expression of VEGF,VEGFR2,bFGF,and FGFR1 in ox-LDL-induced HUVECs.However,the effects of TMP-PF on angiogenesis and the expression of miR-126,VEGF,VEGFR2,and FGFR1 were abolished by miR-126 inhibitor.TMP-PF suppressed angiogenesis in AS by regulating miR-126/VEGF/VEGFR2 pathway,which might elucidate the underlying mechanism of TMP-PF in alleviating AS.展开更多
文摘目的探讨血府逐瘀胶囊联合顺铂对小鼠Lewis肺癌移植瘤血管新生及血管内皮生长因子A(VEGFA)、血管内皮细胞生长因子受体2(VEGFR2)表达的影响。方法从75只C57BL/6小鼠中随机取15只作为正常组,其余小鼠均进行Lewis肺癌荷瘤造模。将造模成功的60只小鼠随机分为模型组、顺铂组、血府逐瘀胶囊组、血府逐瘀胶囊联合顺铂组,每组15只。血府逐瘀胶囊组给予血府逐瘀胶囊0.36 g/kg灌胃,模型组给予生理盐水灌胃,均2次/d;顺铂组给予2 mg/kg的顺铂腹腔注射,2 d 1次;血府逐瘀胶囊联合顺铂组给予0.36 g/kg血府逐瘀胶囊灌胃(2次/d)和2 mg/kg的顺铂腹腔注射(2 d 1次);正常组不给予任何干预。各组连续干预15 d后,统计存活率,摘取瘤组织并称量瘤重,计算抑瘤率,免疫组化法检测肿瘤组织中微血管数量,ELISA法测定血浆VEGFA、碱性成纤维细胞生长因子(bFGF)水平,免疫印迹法检测肿瘤组织中VEGFA、VEGFR2蛋白表达情况。结果顺铂组和血府逐瘀胶囊联合顺铂组小鼠存活率明显高于模型组和血府逐瘀胶囊组(P均<0.05);血府逐瘀胶囊联合顺铂组瘤重明显低于其他组(P均<0.05),抑瘤率明显高于顺铂组和血府逐瘀胶囊组(P均<0.05),肿瘤组织中微血管数明显少于模型组和血府逐瘀胶囊组(P均<0.05);顺铂组瘤重明显低于模型组和血府逐瘀胶囊组(P均<0.05),抑瘤率明显高于血府逐瘀胶囊组(P<0.05),肿瘤组织中微血管数明显少于其他组(P均<0.05)。顺铂组血浆VEGFA、bFGF水平和肿瘤组织中VEGFA、VEGFR2蛋白相对表达量均明显低于模型组(P均<0.05);血府逐瘀胶囊联合顺铂组血浆bFGF水平和肿瘤组织中VEGFR2蛋白相对表达量均明显低于模型组(P均<0.05)。结论血府逐瘀胶囊联合顺铂对Lewis肺癌荷瘤小鼠具有显著的抑瘤及抑制肿瘤血管新生的作用,其机制可能与VEGFA/VEGFR2信号通路相关。
基金supported by the National Natural Science Foundation of China(82004193)CACMS Innovation Fund(CI 2021A00914)the Fundamental Research Funds for the Central Public Welfare Research Institutes(ZZ14-YQ-007).
文摘Angiogenesis in atherosclerosis(AS)promotes plaque destabilization.miR-126 has a significant role in angiogenesis.Tetramethylpyrazine(TMP)and paeoniflorin(PF)have anti-atherosclerotic effects.However,the miR-126-related mechanisms of TMP and PF combination(TMP-PF)on angiogenesis in AS have not been understood.To explore the mechanism of TMP-PF on angiogenesis in AS targeting miR-126.Human umbilical vein endothelial cells(HUVECs)were assigned into the control,model,TMP-PF,TMP-PF+miR-126 inhibitor,and simvastatin groups.HUVECs were transfected with miR-126 inhibitor or negative control,incubated with oxidized low-density lipoprotein(ox-LDL)to establish AS model,and then treated with TMP-PF or simvastatin.Cell proliferation,migration,and tube formation assays are conducted,and the expression of angiogenesis-related factors were detected by enzyme-linked immunosorbent assay(ELISA)and Western blotting.The expression level of miR-126 was confirmed by polymerase chain reaction(PCR).0x-LDL promoted HUVECs proliferation,migration,and tube formation,downregulated miR-126 expression,and increased the expression of VEGF,VEGFR2,bFGF,and FGFR1.TMP-PF inhibited proliferation,migration,and tube formation,upregulated miR-126 expression and decreased the expression of VEGF,VEGFR2,bFGF,and FGFR1 in ox-LDL-induced HUVECs.However,the effects of TMP-PF on angiogenesis and the expression of miR-126,VEGF,VEGFR2,and FGFR1 were abolished by miR-126 inhibitor.TMP-PF suppressed angiogenesis in AS by regulating miR-126/VEGF/VEGFR2 pathway,which might elucidate the underlying mechanism of TMP-PF in alleviating AS.